Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

J.P. Morgan Notebook Day 1: Pfizer, Gilead, Alnylam, Novartis, Sarepta, Deal Trends And Cell Therapy Challenges

San Francisco Skyline with Dramatic Clouds at Sunrise, California, USA - Image

Related Content

Iovance Biotherapeutics CEO On TIL Immunotherapy For Solid Tumors

Nov 22 2017

Bristol Values Celgene's Hematology, Immunology Portfolio At $74bn, But Does It Price In Risk?

Jan 04 2019

US Drug Pricing: What A Difference A Year Makes

Jan 02 2019

Autolus Raises $80m To Take T-Cell Engineering To The Next Level

Sep 26 2017

Appointments: Novartis And GSK Announce New R&D Heads, LNC Therapeutics Gets A New CEO, Plus Announcements From Zelluna and BC Platforms

Apr 19 2018

CEO of New UK Cell And Gene Therapy Hub Says 'All Systems Are Go'

Sep 11 2018

Deal Watch: Genentech Gets Down In The Dirt With Lodo Therapeutics

May 11 2018

The Case For CAR-T Grows As Responses Hold Up Longer Term

Dec 21 2018

Related Companies

Sarepta Therapeutics, Inc.

Myonexus Therapeutics, Inc.

Novartis AG

Amgen, Inc.

Pfizer Inc.

Bristol Myers Squibb Company

Carisma Therapeutics Inc.

Iovance Biotherapeutics, Inc.

Bristol Myers Squibb Company

Eli Lilly and Company

Loxo Oncology at Lilly

Alnylam Pharmaceuticals Inc.

Gilead Sciences, Inc.

Autolus Therapeutics plc

Additional Topics

Business Strategies Pricing Debate Commercial BioPharmaceutical

More from Strategy

More from Business

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window